Editas Medicine, Inc. (NASDAQ:EDIT) last session’s volume of 0.74 million shares was lower than its average volume of 0.9 million shares. The stock, after opening at $15.54, hit $16.28 through the close by scoring 4.16%.Editas Medicine, Inc. (EDIT) Analyst Opinion
Editas Medicine, Inc. has a consensus outperform rating from 5 Wall Street analysts, and the number of shares currently sold short amount to at least 17.2% of shares outstanding. The stock sank -8.23% last month and is up 0.31 this year. Wall Street is only getting more bullish on the stock, with 3 of analysts who cover EDIT having a buy-equivalent rating. Analysts have placed a $39.75 price target on Editas Medicine, Inc., suggesting a 144.16% gain from recent close. It’s currently trading about -49.98% below its 52-week high.Editas Medicine, Inc. Earnings Surprise
Editas Medicine, Inc. (EDIT) failed to surprise the stock market in its last reported earnings when it earned -$0.85 a piece versus the consensus-estimated -$0.61. Its revenue totaled $1.4 million up 55.56% from the previous quarter.
This stock (EDIT) is ahead of its 52-week low with 30.97%. Its last month’s stock price volatility remained 6.95% which for the week stands at 6.73%. The share price has moved forward from its 20 days moving average, trading at a distance of 3.27% and stays -9.74% away from its 50 days moving average. Over the last five days, shares have managed 3.56% gains and now is down -8.03% since hitting its 200-day moving average of $19. Editas Medicine, Inc. (EDIT) has made its way to a 12-month decline of -47.99%.
Turning to Novan, Inc. (NASDAQ:NOVN), its shares were trading at $3.94 a retreat of $-0.37, on the trading floor. The stock, after opening at $4.31, touched a high of $4.31 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.3. Novan, Inc. has 6 buy ratings, 16 holds and 0 sells even after the stock tumbled -87.25% from its high of $30.9 to a $68.79 million market value through last close.Novan, Inc. (NOVN) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 2.55 to 2.5 during a month. Analysts set a 12-month price target of $14 a share. The target implies a 255.33% spike from where the shares are currently trading. Also, the current price highlights a discount of 483.76% to analysts’ high consensus price target.Novan, Inc. (NASDAQ:NOVN) Intraday Trading
The counter witnessed a trading volume of 0.19 million shares versus an average volume of 0.19 million shares during last trading session. Its last month’s stock price volatility remained 6.3% which for the week approaches 5.65%. The lowest price the stock reached in the last trading day was $3.94 and compares with the $3.52 52-week low. The stock recovered 11.93% since its low point and has performed -85.42% year-to-date.